1-8 of 8
Raija Silvennoinen, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Muntasir M Majumder, MSc, MPharm, David Tamborero, PhD, Pekka Anttila, MD, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Ashwini Kumar, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Esa Jantunen, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2016) 128 (22): 198.
https://doi.org/10.1182/blood.V128.22.198.198
Published: 2016
Journal Articles

RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Juha Lievonen, MD, Tuomas Selander, MSc, Imre Västrik, Dr, PhD, Tarja-Terttu Pelliniemi, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 676.
https://doi.org/10.1182/blood.V128.22.676.676
Published: 2016
Journal Articles

A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Tuomas Selander, MSc, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MDPhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1977.
https://doi.org/10.1182/blood.V126.23.1977.1977
Published: 2015
Journal Articles

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc,MPharm, Raija Silvennoinen, MD, Pekka Anttila, MD, David Tamborero, PhD, Samuli Eldfors, MSc, Juha Lievonen, MD, Riikka J Karjalainen, Heikki Kuusanmäki, MSc, Alun Parsons, Minna Suvela, Kimmo Porkka, MD PhD, Caroline Heckman
Journal: Blood
Blood (2015) 126 (23): 3006.
https://doi.org/10.1182/blood.V126.23.3006.3006
Published: 2015
Journal Articles

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD, Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Pekka Anttila, MD, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, BSc, Marjanna Säily, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 3351.
https://doi.org/10.1182/blood.V124.21.3351.3351
Published: 2014
Journal Articles

A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

Raija Silvennoinen, MD, Tuija Lundan, PhD, Pekka Anttila, MD, Jouni Heiskanen, MD, Marjaana Säily, MDPhD, Timo Siitonen, MDPhD, Sakari Kakko, MDPhD, Hanna Ollikainen, MD, Seppo Vanhatalo, MD, Mervi Putkonen, MDPhD, Venla Terävä, MD, Anu Kutila, MD, Mari Partio, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MDPhD, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MDPhD
Journal: Blood
Blood (2014) 124 (21): 847.
https://doi.org/10.1182/blood.V124.21.847.847
Published: 2014
Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 2046.
https://doi.org/10.1182/blood.V124.21.2046.2046
Published: 2014
Journal Articles

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Raija Silvennoinen, MD, Muntasir Mamun Majumder, MSc,BPharm, David Tamborero, PhD, Pekka Anttila, MD, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjaana Säily, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 646.
https://doi.org/10.1182/blood.V124.21.646.646
Published: 2014